001367.SHE Zhejiang Haisen Pharmaceutical Co. Ltd. A
- Market cap
- CNY 2.95B
- P/E
- 19.5x
- P/B
- 1.79x
- ROE
- 8.5%
- Dividend yield
- 0.59%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 001367.SHE undervalued?
Graham number001367.SHE trades 24.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Haisen Pharmaceutical Co. Ltd. A fundamental analysis
No fundamental analysis for Zhejiang Haisen Pharmaceutical Co. Ltd. A yet.
Zhejiang Haisen Pharmaceutical Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Haisen Pharmaceutical Co. Ltd. A
Zhejiang Haisen Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and preparations in China and internationally. The company offers active pharmaceutical ingredients for use as antilipemic agents, antipyretic analgesics, antidepressants, analgesics, antibacterial agents, histamine drugs, and anticonvulsants, as well as for anti-gastric ulcers…
Full company profileZhejiang Haisen Pharmaceutical Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Haisen Pharmaceutical Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 389M | 423M | 397M | 472M | 532M | 510M |
| Gross Profit | 156M | 158M | 163M | 196M | 243M | 241M |
| Operating Income | 110M | 116M | 109M | 125M | 149M | 150M |
| EBITDA | - | 138M | 134M | 159M | 181M | 155M |
| Net Income | 94.0M | 108M | 105M | 123M | 136M | 135M |
| EPS | 0.84 | 0.96 | 0.70 | 0.81 | 0.89 | 0.89 |
| Balance Sheet | ||||||
| Total Assets | 477M | 566M | 1.34B | 1.49B | 1.63B | 1.72B |
| Total Liabilities | 116M | 96.6M | 91.6M | 142M | 136M | 139M |
| Shareholders' Equity | 361M | 469M | 1.25B | 1.34B | 1.49B | 1.59B |
| Cash & Short-term Investments | 205M | 247M | 944M | 1.03B | 909M | 518M |
| Cash Flow | ||||||
| Operating Cash Flow | 107M | 74.9M | 80.6M | 167M | 177M | - |
| Capital Expenditure | 33.3M | 20.2M | 57.4M | 64.7M | 152M | 55.3M |
| Free Cash Flow | 73.7M | 54.8M | 23.2M | 102M | 25.2M | 135M |
| Ratios | ||||||
| ROE | 26.0% | 22.9% | 8.4% | 9.1% | 9.1% | 8.5% |
| ROA | 19.7% | 19.0% | 7.8% | 8.2% | 8.3% | 7.8% |
| Net Profit Margin | 24.2% | 25.4% | 26.3% | 26.0% | 25.5% | 26.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Zhejiang Haisen Pharmaceutical Co. Ltd. A dividends
- Dividend yield
- 0.59%
- Forward dividend
- 0.12 CNY
- Payout ratio
- 12.8%
- Ex-dividend date
- May 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 17.5M | 0.11 | 12.8% |
| 2024 | CNY 34.0M | 0.22 | 27.7% |
| 2023 | - | - | - |
| 2022 | CNY 713K | 0.01 | 0.7% |
| 2021 | CNY 16.4M | 0.15 | 17.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.48:1 on May 20, 2025.
Who owns Zhejiang Haisen Pharmaceutical Co. Ltd. A
- Insiders 77.38%
- Institutions 0.20%
- Public & others 22.43%
- Shares outstanding 152M
- Free float 40.6M
Zhejiang Haisen Pharmaceutical Co. Ltd. A company profile
- Company name
- Zhejiang Haisen Pharmaceutical Co. Ltd. A
- Ticker
- 001367.SHE
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 705
- Fiscal year end
- December
- Address
- Xiangtan Village, Dongyang, China, 322104
- Phone
- 86 579 8677 3082
- Website
- haisenpharma.com
About Zhejiang Haisen Pharmaceutical Co. Ltd. A
Zhejiang Haisen Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and preparations in China and internationally. The company offers active pharmaceutical ingredients for use as antilipemic agents, antipyretic analgesics, antidepressants, analgesics, antibacterial agents, histamine drugs, and anticonvulsants, as well as for anti-gastric ulcers, and digestive and cardiovascular applications. It also provides chemical products for use as paroxetine HCl and amikacin sulphate intermediates and food additives; and escitalopram oxalate tablets to treat depression and panic disorders under the Tezi brand. In addition, the company engages in the import and export of goods; trading; and medical research and experimental development activities. Zhejiang Haisen Pharmaceutical Co., Ltd. was incorporated in 1998 and is headquartered in Dongyang, China.
Zhejiang Haisen Pharmaceutical Co. Ltd. A management
6- Ms. Aijuan PanChief Financial Officer · born 1962
- Mr. Kangkang HuCompany Secretary · born 1973
- Mr. Yangkuan WuDeputy General Manager · born 1993
- Mr. Sheng-Quan ZhangDeputy General Manager · born 1969
- Mr. Yanjun LouDeputy General Manager · born 1967
- Mr. Lin AiGM & Director · born 1961